Related Experiment Video
Updated: Jul 22, 2025

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
Published on: July 21, 2023
A systematic review and meta-analysis of the effect of high-intensity statin on coronary microvascular dysfunction
Bihan Huang1, Xueying Han2, Yun Pan3
1Department of Cardiology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, China. huangbihan1991@163.com.
Insights
High-intensity statin pretreatment significantly improves coronary microvascular function after percutaneous coronary intervention (PCI). This meta-analysis found improved thrombolysis in myocardial infarction (TIMI) and index of microvascular resistance (IMR) in patients with coronary heart disease.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Coronary microvascular dysfunction is a significant complication in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI).
- The role of high-intensity statin pretreatment in mitigating this dysfunction remains an area of active investigation.
Conclusions:
- High-intensity statin pretreatment demonstrates a beneficial effect on coronary microvascular function, specifically improving TIMI flow and IMR after PCI.
- Further high-quality, large-scale RCTs are warranted to confirm these findings and explore optimal treatment strategies.
Objective:
The purpose of this meta-analysis is to evaluate the role of high-intensity statin pretreatment on coronary microvascular dysfunction in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI).
Methods:
PubMed, Cochrane, and Embase were searched. This meta-analysis selection included randomized controlled trials (RCTs), involving high-intensity statin pretreatment as active treatment, and measurement of thrombolysis in myocardial infarction (TIMI), myocardial blush grade (MBG) or index of microvascular resistance (IMR) in coronary heart disease (CHD) patients undergoing PCI. I2 test was used to evaluate heterogeneity. Pooled effects of continuous variables were reported as Standard mean difference (SMD) and 95% confidence intervals (CI). Pooled effects of discontinuous variables were reported as risk ratios (RR) and 95% confidence intervals (CI). Random-effect or fix-effect meta-analyses were performed. The Benefit was further examined based on clinical characteristics including diagnosis and statin type by using subgroup analyses. Publication bias was examined by quantitative Egger's test and funnel plot. We performed sensitivity analyses to examine the robustness of pooled effects.
Results:
Twenty RCTs were enrolled. The data on TIMI < 3 was reported in 18 studies. Comparing with non-high-intensity statin, high-intensity statin pretreatment significantly improved TIMI after PCI (RR = 0.62, 95%CI: 0.50 to 0.78, P < 0.0001). The data on MBG < 2 was reported in 3 studies. The rate of MBG < 2 was not different between groups (RR = 1.29, 95% CI: 0.87 to 1.93, P = 0.21). The data on IMR was reported in 2 studies. High-dose statin pretreatment significantly improved IMR after PCI comparing with non-high-dose statin (SMD = -0.94, 95% CI: -1.47 to -0.42, P = 0.0004). There were no significant between-subgroup differences in subgroups based on statin type and diagnosis. Publication bias was not indicated by using quantitative Egger's test (P = 0.97) and funnel plot. Sensitivity analyses confirmed the robustness of these findings.
Conclusions:
Comparing with non-high-intensity statin, high-intensity statin pretreatment significantly improved TIMI and IMR after PCI. In the future, RCTs with high quality and large samples are needed to test these endpoints.
More Related Videos
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
09:15Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis III: Management
Coronary Artery Disease II: Pathophysiology
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease V: Interprofessional Care